Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy

Area of Science:

• Immunology
• Biochemistry
• Pharmacology

Background:

• Programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) interaction inhibits T cell activation, enabling tumors to evade immune surveillance.
• Upregulation of PD-L1 by tumor tissues is a key mechanism for immune evasion.
• Discovering natural metabolites that regulate PD-L1 could lead to novel immunotherapies.

Purpose of the Study:

• To identify natural metabolites that regulate PD-L1 expression.
• To elucidate the mechanism by which pyridoxal (PL) affects PD-L1.
• To evaluate the functional impact of PL on T cell activity and its potential in cancer immunotherapy.

Main Methods:

• Metabolite library screening to identify PD-L1 regulators.
• Proteasome-dependent degradation assays to study PD-L1 turnover.
• E3 ligase identification assays using STUB1.
• T cell killing assays to assess functional immune response.

Main Results:

• Pyridoxal (PL) was identified as a significant suppressor of PD-L1 expression.
• PL enhances PD-L1 degradation through a proteasome-dependent pathway.
• STUB1 was identified as the E3 ligase involved in PL-mediated PD-L1 degradation.
• PL treatment enhanced T cell killing activity by blocking the PD-1/PD-L1 signaling pathway.

Conclusions:

• Pyridoxal (PL) acts as an inhibitor of PD-L1, promoting its degradation.
• PL's mechanism involves STUB1-mediated ubiquitination and proteasomal degradation of PD-L1.
• PL enhances anti-tumor T cell activity, presenting a viable option for combination immunotherapy.